Human induced pluripotent stem cells (hiPSC) have been generated from different tissues, with the age of the donor, tissue source and specific cell type influencing the reprogramming process. Reprogramming hematopoietic progenitors to hiPSC may provide a very useful cellular system for modelling blood diseases. We report the generation and complete characterization of hiPSCs from human neonatal fibroblasts and cord blood (CB)-derived CD34+ hematopoietic progenitors using a single polycistronic lentiviral vector containing an excisable cassette encoding the four reprogramming factors Oct4, Klf4, Sox2 and c-myc (OKSM). The ectopic expression of OKSM was fully silenced upon reprogramming in some hiPSC clones and was not reactivated upon differentiation, whereas other hiPSC clones failed to silence the transgene expression, independently of the cell type/tissue origin. When hiPSC were induced to differentiate towards hematopoietic and neural lineages those hiPSC which had silenced OKSM ectopic expression displayed good hematopoietic and early neuroectoderm differentiation potential. In contrast, those hiPSC which failed to switch off OKSM expression were unable to differentiate towards either lineage, suggesting that the residual expression of the reprogramming factors functions as a developmental brake impairing hiPSC differentiation. Successful adenovirus-based Cre-mediated excision of the provirus OKSM cassette in CB-derived CD34+ hiPSC with residual transgene expression resulted in transgene-free hiPSC clones with significantly improved differentiation capacity. Overall, our findings confirm that residual expression of reprogramming factors impairs hiPSC differentiation.
References
[1]
Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, et al. (2008) Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 105: 2883–2888.
[2]
Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, et al. (2007) Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1: 55–70.
[3]
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
[4]
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.
[5]
Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797–801.
[6]
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
[7]
Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodriguez-Piza I, et al. (2009) Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5: 353–357.
[8]
Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, et al. (2009) Direct reprogramming of human neural stem cells by OCT4. Nature 461: 649–643.
[9]
Kim PG, Daley GQ (2009) Application of induced pluripotent stem cells to hematologic disease. Cytotherapy 11: 980–989.
[10]
Hanley PJ, Cruz CR, Shpall EJ, Bollard CM (2010) Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy 12: 713–720.
[11]
Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, et al. (2009) Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5: 434–441.
[12]
Menendez P, Caballero MD, Prosper F, Del Canizo MC, Perez-Simon JA, et al. (2002) The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 42: 1159–1172.
[13]
Menendez P, del Canizo MC, Orfao A (2001) Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells. J Biol Regul Homeost Agents 15: 53–61.
[14]
Menendez P, Perez-Simon JA, Mateos MV, Caballero MD, Gonzalez M, et al. (2002) Influence of the different CD34+ and CD34？ cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. Br J Haematol 119: 135–143.
[15]
Menendez P, Prosper F, Bueno C, Arbona C, San Miguel JF, et al. (2001) Sequential analysis of CD34+ and CD34？ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. Leukemia 15: 430–439.
[16]
Takenaka C, Nishishita N, Takada N, Jakt LM, Kawamata S (2010) Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp Hematol 38: 154–162.
[17]
Ye Z, Zhan H, Mali P, Dowey S, Williams DM, et al. (2009) Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114: 5473–5480.
[18]
Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD, et al. (2010) Exceision of Reprogramming Transgenes Improves the Differentiation Potential of iPS Cells Generated with a Single Excisable Vector. STEM CELLS 28: 64–74.
[19]
Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, et al. (2009) Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. STEM CELLS 27: 543–549.
[20]
Kim K, Doi A, Wen B, Ng K, Zhao R, et al. (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467: 285–290.
[21]
Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, et al. (2010) Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28: 848–855.
[22]
Bueno C, Catalina P, Melen GJ, Montes R, Sanchez L, et al. (2009) Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 30: 1628–1637.
[23]
Bueno C, Montes R, Menendez P (2010) The ROCK Inhibitor Y-27632 Negatively Affects the Expansion/Survival of Both Fresh and Cryopreserved Cord Blood-Derived CD34+ Hematopoietic Progenitor Cells. Stem Cell Rev 6: 215–223.
[24]
Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, et al. (2011) Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 117: 4746–4758.
[25]
Suhr ST, Chang EA, Rodriguez RM, Wang K, Ross PJ, et al. (2009) Telomere dynamics in human cells reprogrammed to pluripotency. PLoS One 4: e8124.
[26]
Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, Melen GJ, Sanchez L, et al. (2008) Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 28: 6609–6619.
[27]
Menendez P, Catalina P, Rodriguez R, Melen GJ, Bueno C, et al. (2009) Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 206: 3131–3141.
[28]
Montes R, Ligero G, Sanchez L, Catalina P, de la Cueva T, et al. (2009) Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF-beta and IGF-II. Cell Res 19: 698–709.
[29]
Cortes JL, Sanchez L, Catalina P, Cobo F, Bueno C, et al. (2008) Whole-blastocyst culture followed by laser drilling technology enhances the efficiency of inner cell mass isolation and embryonic stem cell derivation from good- and poor-quality mouse embryos: new insights for derivation of human embryonic stem cell lines. Stem Cells Dev 17: 255–267.
[30]
Cortes JL, Sanchez L, Ligero G, Gutierrez-Aranda I, Catalina P, et al. (2009) Mesenchymal stem cells facilitate the derivation of human embryonic stem cells from cryopreserved poor-quality embryos. Hum Reprod 24: 1844–1851.
[31]
Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, et al. (2010) Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 28: 1568–1570.
[32]
Bueno C, Montes R, Melen GJ, Ramos-Mejia V, Real PJ, et al. (2012) A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res. (in press).
[33]
Sanchez L, Gutierrez-Aranda I, Ligero G, Martin M, Ayllon V, et al. (2012) Maintenance of Human Embryonic Stem Cells in Media Conditioned by Human Mesenchymal Stem Cells Obviates the Requirement of Exogenous Basic Fibroblast Growth Factor Supplementation. Tissue Eng Part C Methods. (in press).
[34]
Catalina P, Bueno C, Montes R, Nieto A, Ligero G, et al. (2009) Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia. Leuk Res 33: 980–990.
[35]
Catalina P, Cobo F, Cortes JL, Nieto AI, Cabrera C, et al. (2007) Conventional and molecular cytogenetic diagnostic methods in stem cell research: a concise review. Cell Biol Int 31: 861–869.
[36]
Catalina P, Montes R, Ligero G, Sanchez L, de la Cueva T, et al. (2008) Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol Cancer 7: 76.
[37]
Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, et al. (2010) Deficiency in p53 but not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells In vitro and Initiates Leiomyosarcoma In vivo. Cancer Res 70: 4185–4194.
[38]
Menendez P, Wang L, Chadwick K, Li L, Bhatia M (2004) Retroviral transduction of hematopoietic cells differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol Ther 10: 1109–1120.
[39]
Shojaei F, Menendez P (2008) Molecular profiling of candidate human hematopoietic stem cells derived from human embryonic stem cells. Exp Hematol 36: 1436–1448.
[40]
Wang L, Menendez P, Cerdan C, Bhatia M (2005) Hematopoietic development from human embryonic stem cell lines. Exp Hematol 33: 987–996.
[41]
Menendez P, Bueno C, Wang L (2006) Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy 8: 530–541.
[42]
Ramos-Mejia V, Melen GJ, Sanchez L, Gutierrez-Aranda I, Ligero G, et al. (2010) Nodal/Activin signaling predicts human pluripotent stem cell lines prone to differentiate towards the hematopoietic lineage. Mol Ther 18: 2173–2181.
[43]
Wang L, Li L, Shojaei F, Levac K, Cerdan C, et al. (2004) Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 21: 31–41.
[44]
Wang L, Menendez P, Shojaei F, Li L, Mazurier F, et al. (2005) Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 201: 1603–1614.
[45]
Bueno C, Montes R, Martin L, Prat I, Hernandez MC, et al. (2008) NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia 22: 1475–1478.
[46]
Calvanese V, Horrillo A, Hmadcha A, Suarez-Alvarez B, Fernandez AF, et al. (2008) Cancer genes hypermethylated in human embryonic stem cells. PLoS One 3: e3294.
[47]
Pankratz MT, Li XJ, Lavaute TM, Lyons EA, Chen X, et al. (2007) Directed neural differentiation of human embryonic stem cells via an obligated primitive anterior stage. Stem Cells 25: 1511–1520.
[48]
Menendez P, Wang L, Bhatia M (2005) Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther 5: 375–385.
[49]
Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al. (2009) Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 27: 1033–1037.
[50]
Subramanyam D, Blelloch R (2009) Watching reprogramming in real time. Nat Biotechnol 27: 997–998.
[51]
Broxmeyer HE (2010) Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell 6: 21–24.
[52]
Ramos-Mejia V, Bueno C, Roldan M, Sanchez L, Ligero G, et al. (2011) The adaptation of Human Embryonic Stem Cells to different feeder-free culture conditions is accompanied by a mitochondrial response. Stem Cells Dev.
[53]
Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, et al. (2009) Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nature Genetics 41: 968–976.
[54]
Hasegawa K, Zhang P, Wei Z, Pomeroy JE, Lu W, et al. (2010) Comparison of Reprogramming Efficiency Between Transduction of Reprogramming Factors, Cell-Cell Fusion, and Cytoplast Fusion. Stem Cells 28: 1338–1348.
[55]
Muller LU, Daley GQ, Williams DA (2009) Upping the ante: recent advances in direct reprogramming. Mol Ther 17: 947–953.
[56]
Liang G, Taranova O, Xia K, Zhang Y (2010) Butyrate promotes iPS cell generation. J Biol Chem 285: 25516–25521.
[57]
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, et al. (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26: 795–797.
[58]
Fussner E, Djuric U, Strauss M, Hotta A, Perez-Iratxeta C, et al. (2011) Constitutive heterochromatin reorganization during somatic cell reprogramming. The EMBO journal 30: 1778–1789.
[59]
Hotta A, Ellis J (2008) Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. Journal of cellular biochemistry 105: 940–948.
[60]
Rastegar M, Hotta A, Pasceri P, Makarem M, Cheung AY, et al. (2009) MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PLoS One 4: e6810.
[61]
Calvanese V, Fernandez AF, Urdinguio RG, Suarez-Alvarez B, Mangas C, et al. (2012) A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acid Res 40: 116–131.
[62]
Ramos-Mejia V, Fernandez AF, Ayllon V, Real PJ, Bueno C, et al. (2012) Maintenance of human embryonic stem cells in mesenchymal stem cell-conditioned media augments hematopoietic specification. Stem Cells Dev. (in press).
